As Pink October brings breast cancer awareness to the forefront, Vivian has taken a monumental step by securing a new drug in the treatment of breast cancer on Malta's national formulary, giving Maltese patients broader access to this vital therapy, which had previously been available only privately.
The CDK4/6 inhibitor is an established drug for treating certain types of hormone receptor-positive breast cancer, particularly in metastatic cases. It inhibits specific proteins that fuel cancer cell growth, slowing the progression of the disease and providing patients with better outcomes and improved quality of life.
"As we commemorate Pink October, this achievement moves us beyond awareness campaigns to tangible, impactful action," says Kenneth Briffa from Vivian.
Statistics published earlier in June of this year showed that of the 48 oncology products approved by the EU between 2019 and 2022, 54% were unavailable in Malta, with 46% accessible only through private healthcare, placing Malta at the bottom of a survey of 37 European countries. This means that out of the 48 EU-approved oncology products, 22 were available exclusively through private channels and 26 were entirely unavailable.*
"In light of these concerning statistics, Vivian's success in getting this important drug for the treatment of breast cancer on the national formulary is a critical advancement in patient care, ensuring that breast cancer patients can access treatment without facing prohibitive costs or restricted availability," added Mr Briffa.
Denise Borg Manche, Managing Director at Vivian added: "Securing formulary approval is a lengthy and intricate process, often the culmination of years of dedicated efforts to educate and raise awareness within the medical community about the unmet medical need for such treatments."
"This newly added treatment is a significant step forward in breast cancer treatment which reflects Vivian's ongoing commitment to securing life-saving medicines for all. Of course, different patients will need different therapies as one size does not fit all. This is why we will always advocate for the consideration and introduction of not only one treatment per indication, but more than one treatment so patients will receive the right treatment from the onset, for the best patient outcomes.
Real progress in cancer care demands action and perseverance. We will continue working with stakeholders to enhance access to treatments across Malta and shall remain committed to ensuring that the right medication reaches the right patient at the right time," concluded Denise Borg Manche.
*EFPIA Patients Waiting to Access Innovation Therapies (W.A.I.T.)